CD33 (SIGLEC3) Antibody (N-term) Blocking peptide
€363.00
In stock
SKU
AC-BP1622a
Background:
SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2,6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.
Other Names:
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1622a was selected from the N-term region of human SIGLEC3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CD33
Gene ID: 945
Primary Accession: P20138
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2,6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.
Other Names:
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1622a was selected from the N-term region of human SIGLEC3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CD33
Gene ID: 945
Primary Accession: P20138
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review